VEGF Overexpression is a Valuable Prognostic Factor for Non-Hodgkin's Lymphoma Evidence from a Systemic Meta-analysis

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2015 Mar 27

PMID 25810565

Citations 17

Authors

Jing Yang

Wenlu Li

Xin He

Guofei Zhang

Lan Yue

Ying Chai

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) plays a vital role in the progression of Non-Hodgkin's lymphoma (NHL). Although multiple studies have investigated the relationship between VEGF expression and prognosis of NHL, these studies have yielded conflicting results. Therefore, we performed a meta-analysis to evaluate the role of VEGF in the prognosis of NHL patients. We systematically searched eligible studies from databases and determined that there was a significant correlation between VEGF overexpression and overall survival (HR (hazard ratio) = 1.66, 95% CI: 1.25-2.22, P = 0.001). Based on subgroup analysis by study location, number of patients, the source of VEGF expression, and study design, we found that VEGF overexpression in surgically resected tissue (HR = 1.95, 95% CI: 1.41-2.69, P = 0.000), but not in serum (HR = 1.37, 95% CI: 0.96-1.95, P = 0.087), was associated with poorer prognosis. Additionally, VEGF overexpression did not correlate with performance status, LDH level, IPI score, tumor staging, B symptoms, or NHL relapse. In summary, overexpression of VEGF in lymphoma tissue represents a promising potential prognostic factor in NHL.

Citing Articles

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Gonzalez-Kozlova E, Huang H, Jagede O, Tuballes K, Del Valle D, Kelly G Cancer Res Commun. 2024; 4(7):1726-1737.

PMID: 38934093 PMC: 11247952. DOI: 10.1158/2767-9764.CRC-24-0252.

Macrophages and angiogenesis in human lymphomas.

Ribatti D, Tamma R, Annese T, Ingravallo G, Specchia G Clin Exp Med. 2024; 24(1):26.

PMID: 38285283 PMC: 10824884. DOI: 10.1007/s10238-023-01291-y.

The expression of hypoxia inducible factor-1 alpha in diffuse large B-cell lymphoma (DLBCL) patients: a cross-sectional study in Indonesia.

Pangarsa E, Rizky D, Tandarto K, Naibaho R, Kurniawan S, Istiadi H Ann Med Surg (Lond). 2023; 85(10):4780-4787.

PMID: 37811023 PMC: 10553143. DOI: 10.1097/MS9.0000000000001162.

The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy.

Das K, Mukherjee T, Shankar P Biomolecules. 2023; 13(6).

PMID: 37371477 PMC: 10296653. DOI: 10.3390/biom13060897.

Preliminary study of hypoxia markers in diffuse large B-cell lymphoma.

Pangarsa E, Wuryantoro P, Naibaho R, Setiawan B, Santosa D, Istiadi H Mol Clin Oncol. 2022; 17(3):140.

PMID: 35949890 PMC: 9353874. DOI: 10.3892/mco.2022.2573.

References

Rujirojindakul P, Lekhakula A . Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas. ScientificWorldJournal. 2012; 2012:215231. PMC: 3351040. DOI: 10.1100/2012/215231. View

Gerber H, Malik A, Solar G, Sherman D, Liang X, Meng G . VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002; 417(6892):954-8. DOI: 10.1038/nature00821. View

Jiang W, Martin T, Parr C, Davies G, Matsumoto K, Nakamura T . Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2004; 53(1):35-69. DOI: 10.1016/j.critrevonc.2004.09.004. View

Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S . Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2002; 68(2):91-100. DOI: 10.1034/j.1600-0609.2002.01609.x. View

Ganjoo K, Moore A, Orazi A, Sen J, Johnson C, An C . The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol. 2007; 134(3):381-7. DOI: 10.1007/s00432-007-0294-x. View

Poh C, Shi Z, Lim T, Neoh K, Wang W . The effect of VEGF functionalization of titanium on endothelial cells in vitro. Biomaterials. 2009; 31(7):1578-85. DOI: 10.1016/j.biomaterials.2009.11.042. View

Gratzinger D, Zhao S, Tibshirani R, Hsi E, Hans C, Pohlman B . Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 2007; 88(1):38-47. DOI: 10.1038/labinvest.3700697. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y . Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma. 2010; 52(1):46-52. DOI: 10.3109/10428194.2010.529204. View

10.

Stopeck A, Unger J, Rimsza L, Bellamy W, Iannone M, Persky D . A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma. 2009; 50(5):728-35. PMC: 3532923. DOI: 10.1080/10428190902856808. View

11.

Ganjoo K, An C, Robertson M, Gordon L, Sen J, Weisenbach J . Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006; 47(6):998-1005. DOI: 10.1080/10428190600563821. View

12.

Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R . Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000; 18(7):1423-31. DOI: 10.1200/JCO.2000.18.7.1423. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F . Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol. 1996; 56(1-2):45-53. DOI: 10.1111/j.1600-0609.1996.tb00293.x. View

15.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

16.

Kim J, Kim S, Do I, Jin J, Nam D, Ko Y . Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?. Leuk Lymphoma. 2011; 52(2):205-13. DOI: 10.3109/10428194.2010.542261. View

17.

Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne C . The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002; 16(13):1802-4. DOI: 10.1096/fj.02-0109fje. View

18.

Jacobson M, Burne J, King M, Miyashita T, Reed J, Raff M . Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature. 1993; 361(6410):365-9. DOI: 10.1038/361365a0. View

19.

Shweiki D, Itin A, Soffer D, Keshet E . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359(6398):843-5. DOI: 10.1038/359843a0. View

20.

Ferrara N, Hillan K, Gerber H, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5):391-400. DOI: 10.1038/nrd1381. View